Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and Ozempic

Novo Nordisk president and CEO Lars Fruergaard Jørgensen joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported better-than-expected 2023 earnings, surging demand for Wegovy and Ozempic, and more.

[@michaelskyros8803]

It's always about the money.

[@user-221i]

He didn't answer the question.

[@michaelskyros8803]

Everything is always about money

[@zacharythomas9306]

It’s odd how once the price of insulin began to be regulated the kind pharmaceutical companies were able to develop $900/month alternatives.

[@michaelskyros8803]

It's always about the money.